Positioned to deliver revolutionary cancer vaccines

Dr. Kwok is a clinician scientist and Cancer Research UK (CRUK) cancer vaccines fellow at Oxford University. He enjoys more than two decades of professional experience across the fields of oncology, vaccinology, clinical trials, strategy consulting and investment banking. He co-founded Infinitopes Precision Immunomics in 2021, bringing together world leading experts in antigen discovery, T-cell immunology, computation/ML, vaccine design/molecular biology, biomanufacturing and medicines regulation. His mission is to develop accessible, high efficiency vaccines to prevent cancer metastases. Reach out via LinkedIn for partnerships and collaborations.

Dr. Lian Ni Lee, a seasoned immunologist, earned her Ph.D. in Immunology from University College London (UCL) and subsequently gained diverse industry and academic experiences at GSK, Pfizer, San Diego and most recently at Oxford University. With over a decade of deep expertise in T cell immunology, Dr. Lee has been instrumental in building Infinitopes' laboratory team, nurturing exceptional scientists from the Oxford Vaccine Group and beyond. Before joining Infinitopes, she spearheaded ground-breaking research, funded by CRUK and the Emerson Collective, focused on developing innovative cancer vaccines, showcasing her commitment to advancing the forefront of immunological research.

Dr. Senthil Chinnakannan, a distinguished vaccine designer and molecular biology expert, holds a Ph.D. in Molecular Virology from the University of London. Renowned for his serial contributions to vaccine development, Dr. Chinnakannan played a pivotal role in co-developing University of Oxford's multi-antigen vaccines for Hepatitis B, Hepatitis C, Influenza, COVID-19, and cancer. His expertise extends to addressing intricate technical challenges associated with multi-epitope vaccines, solidifying his standing as a world expert in the field. Prior to joining Infinitopes, Dr. Chinnakannan holds credit for inventing and contributing to five vaccine patents for the Univ. of Oxford, showcasing his commitment to advancing immunological innovation.

Professor Paul Klenerman, winner of CRUK Cancer Immunology Project Award, is a key opinion leader in the immunology field and a clinical virology and honorary consultant at the University of Oxford. Paul Klenerman trained in infectious diseases at Cambridge and Oxford and holds the Truelove chair in the Department of Medicine at Oxford. As the co-discoverer of MAIT cells, he has worked on T cell responses in infection, especially HCV, and T cell memory to vaccines, including immunological memory. Much of the recent work in his lab focuses on emerging functions of innate-like T cell subsets and their role in disease.

Professor Mark middleton is Director of the CRUK Oxford Centre and Head of Oncology at the University of Oxford, where he founded the Early Phase Clinical Trials Unit (EPCTU). He trained in medicine and cricket at Gonville and Caius College, Cambridge before defecting to Oxford. He did his PhD in Oncology at the Christie Hospital and University of Manchester. His clinical and research interests are in new cancer drug development and the treatment of upper GI cancers and melanoma. Mark has been Chief or Principal Investigator on >100 trials and closely involved in the development of new treatments including DNA repair, immune checkpoint and kinase inhibitors, ImmTACs and oncolytic viruses making him a global thought leader in cancer immunotherapies.

Professor Teresa Lambe is the Calleva Head of Vaccine Immunology and a Professor of Vaccinology & Immunology and PSI Investigator at University of Oxford. Prof Lambe co-designed the Oxford/AstraZeneca vaccine in January 2020, and oversaw the delivery of the immune results needed to support regulatory approval in late 2020. Prof. Lambe was appointed as an honorary OBE for her services to Sciences and Public Health in the 2021 Queen’s Birthday Honours and recieved the Presidential Distinguished Service Award for the Irish Abroad in 2022. The Lambe group is currently developing and testing vaccines against a number of outbreak pathogens including a vaccine against Ebola virus diseases (ChAdOx1 biEBOV). In 2023, the team's candidate vaccine against Marburg virus disease was selected by WHO for inclusion in trials to combat Marburg virus disease.

Dr Green has a long-standing research interest in mechanisms of DNA replication and genome stability (with a PhD from UCL in Biochemistry and post-doctoral work in Paris, Sussex and Cambridge). Since 2018, she has headed the Clinical BioManufacturing Facility (CBF), and alongside her team, produced high quality clinical vaccine products for use in first-in-human clinical trials. They made vaccines for academics in Oxford for 20+ years, including vaccines for malaria, rabies, plague, ebola, zika and many others. The CBF made the first batches of the Oxford ChADOx1 COVID vaccine in record time in 2020, and supported AstraZeneca with its eventual delivery of more than 2 billion doses during the pandemic.